Claims for Patent: 9,216,179

Summary for Patent: 9,216,179

Title:	Treatment of gout and hyperuricemia
Abstract:	Sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylt- hio)acetate is described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are described.
Inventor(s):	Miner; Jeffrey (San Diego, CA), Girardet; Jean-Luc (San Diego, CA), Quart; Barry D. (Encinitas, CA)
Assignee:	ARDEA BIOSCIENCES, INC. (San Diego, CA)
Application Number:	13/704,192
Patent Claims:	1. A method of reducing serum uric acid levels, treating hyperuricemia, or treating gout in a human comprising co-administration of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)ace- tate, or a pharmaceutically acceptable salt thereof, and allopurinol to the human, wherein said method provides serum urate levels of less than 6 mg/dL; and wherein said method results in an adverse event in less than 15% of the humans. 2. A method of reducing serum uric acid levels, treating hyperuricemia, or treating gout in a human comprising co-administration of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)ace- tate, or a pharmaceutically acceptable salt thereof, and allopurinol to the human, wherein the serum urate levels are less than 4 mg/dL. 3. A method of reducing serum uric acid levels, treating hyperuricemia, or treating gout in a human comprising co-administration of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)ace- tate, or a pharmaceutically acceptable salt thereof, and allopurinol to the human, wherein said method provides serum urate levels of less than 6 mg/dL; and wherein the method provides a serum urate levels intraday change from baseline of more than 50%. 4. A method of reducing serum uric acid levels, treating hyperuricemia, or treating gout in a human comprising co-administration of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)ace- tate, or a pharmaceutically acceptable salt thereof, and allopurinol to the human, wherein said method provides serum urate levels of less than 6 mg/dL, wherein the gout in the human is characterized by the presence of large accumulated deposits of uric acid or tophi.